Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evenamide adjunctive therapy in symptomatic chronic schizophrenia
2020-006062-36Phase 2Completed
- Sponsor
- Newron Pharmaceuticals
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Evenamide adjunctive treatment with Placebo adjunctive control (2 arms). Primary endpoints: Safety and tolerability of evenamide, Evidence of efficacy of evenamide and 4 more. Started Feb 2021; status: completed.
02
Drugs
evenamide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2020-006062-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006062-36.